ASX Linkedin Twitter               


Analyst Coverage 2016

21 November 2016
CAVATAK Data Continues to Impress

Bell Potter
14 November 2016
CVA21 (CAVATAK) Shows Strong Efficacy In Combination With Pembrolizumab

Roth Capital Partners
13 November 2016
CAPRA and the Double Whammy Against Melanoma

Bioshares Edition 669
14 October 2016
Viralytics’ MITCI Study Reveals Benefits of CAVATAK/Ipilimumab Combo

Bell Potter
13 October 2016
CVA21 (CAVATAK) Shows Strong Efficacy in Combination with Yervoy

Roth Capital Partners
9 October 2016
MITCI Shines at ESMO; Loud Shot Across Imlygic Bow; Target to A$4.50

Roth Capital Partners
30 June 2016
Big Pharma Loves Onco Virus Combinations, and So Do We

Bell Potter
14 June 2016
STORM Trial at ASCO – data sheds more light

10 June 2016
Three Cavatak/checkpoint combination trials – ASCO Update

5 May 2016
Eye-Catching MITCI Data

Bioshares Edition 645
29 April 2016
Viralytics’ Cavatak Delivers Benefits In Combination With Checkpoint Inhibitors

Roth Capital Partners
19 April 2016
CAVATAK Plugging Away on All Fronts; Nice CALM and MITCI Updates

Bell Potter
18 April 2016
MITCI Results Show Promise

Bell Potter
30 March 2016
A Bumper Year for Clinical Results

Bioshares Edition 640
18 March 2016
Positive Early Bladder Cancer Results

Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2017
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).